ERBB2 and breast cancer: Therefore, our data imply that ctDNA might be used to detect chemotherapy‐resistant mutations and predict the drug response in HER2‐ BC patients, encouraging future studies of examining the drug‐resistant mechanism in bigger patient cohorts.